Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

A hot and humid Saturday morning at the Hancock County Fairgrounds saw some 4-H’ers take a small reprieve from the hustle and bustle of the county 4-H fair to take part in the Farmer Olympics.

From frozen tiles in rabbit cages to horse water flavored with Gatorade and iced tea to box fans bungee-corded and zip-tied over stalls, Montcalm County 4-Hers have found creative ways to keep their ...

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Novo Nordisk A/S has scrapped a partnership with Hims & Hers Health Inc after less than two months, saying the US company is ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

BofA analyst Allen Lutz estimates Hims & Hers’ year-over-year core revenue growth has “slowed sharply,” from about 45% in Q3 of 2024 to 29% in Q1 of 2025, despite a tailwind from shifting customers to ...

Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker alleged that ...

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish ...